Paper - WANFANG MED ONLINE

You Position: Home > Paper

Weining granules combined with chemotherapy for recurrent and metastatic gastric cancer

( views:232, downloads:4 )

Author:: No author available

Journal Title:: WORLD CHINESE JOURNAL OF DIGESTOLOGY

Issue:: 2

DOI:: 10.3969/j.issn.1009-3079.2008.02.011

Key Word:: 胃宁颗粒;胃癌;复发;转移

Abstract：目的:研究胃宁颗粒联合化疗对胃癌复发移的防治作用.方法:160例术后胃癌患者随机分为治疗组80予胃宁颗粒配合化疗,对照组80例予单纯化疗.观察治疗前后局部复发及远处转移情况,血液流变学指标血浆黏度、全血黏度、血沉方程(K值)、红细胞聚集指数、纤维蛋白原,金属蛋白酶-9(MMP-9)、血管内皮生长因子(VEGF)含量、复发转移病灶大小,复发转移者生活质量的变化.结果:治疗组1年后复发转移率22.22%,对照组为32.22%,两组比较差异有显著性意义(P＜0.05);治疗组治疗后血浆黏度、全血黏度、纤维蛋白原、MMP-9、VEGF含量与对照组相比显著降低(1.26±0.13 mPa·s vs 1.75±0.11 mPa·s,8.73±1.98 mPa·s vs 20.56±2.31 mPa·s,2.15±0.16 vs 3.85±0.41,135.46±22.16 μg/L vs 186.23±31.56 μg/L,102.46±18.43 vs 176.43±21.56,P＜0.05或P＜0.01);治疗组对复发转移灶大小抑制率为30.00%,对照组为17.85%,两组比较差异有显著性意义(P＜0.05);治疗组对复发转移患者生活质量改善显著优于对照组(P＜0.01).结论:胃宁颗粒和化疗药物联用,具有一定的协同作用,可以提高疗效,改善患者生存质量,其机制可能与改善微循环、降低MMP-9、VEGF含量有关.

Reference

[1]梁健,邓鑫,黄仁彬.胃宁方对人胃癌SGC-7910细胞增殖凋亡的影响[J].2006,(9).
[2]毛志东.100例晚期癌症患者24小时血液流变学变化的观察[J].2003,(1).
[3]Xing-E Liu,Xiao-Dong Sun,Jin-Min Wu.Expression and significance of VEGF-C and FLT-4 in gastric cancer[J].2004,(3).
[4]徐飚,王建明.胃癌流行病学研究[J].2006,(1).
[5]杨金坤,郑坚,沈克平,等.中药胃肠安防治进展期胃癌术后转移的临床研究[J].2003,(8).
[6]沈志祥,董卫国,沈磊,等.胃癌患者血清中MMP-9的水平及其癌组织中MMP-9与VEGF的表达[J].2003,(10).
[7]Jun TIAN,Jian-Shun Chen.Nutritional status and quality of life of the gastric cancer patients in Changle County of China[J].2005,(11).
[8]许玲,魏品康,陈亚琳,等.中药消痰散结方抑制裸鼠原位移植人胃癌SGC-7901的生长转移[J].2004,(5).
[9]孙秀娣,牧人,周有尚,等.中国1990~1992年胃癌死亡调查分析[J].2002,(1).
[10]王璐,张丽红,李玉林,等.基质金属蛋白酶-9及其mRNA在胃癌中的表达与血管新生的关系[J].2003,(9).
[11]许尤琪,薛惠宁,诸晓秋,等.健脾活血解毒中药抗胃癌术后转移的临床观察[J].2003,1(3).
[12]梁健,邓鑫,黄仁彬.胃宁方对人胃癌细胞侵袭能力的影响[J].2006,(7).
[13]汤钊猷主编.现代肿瘤学[M].1993.
[14]Sung-Ae, Jung,Suk-Kyun, Yang,Jeong Sun, Kim,etc.[The expression of matrix metalloproteinases (MMPs), tissue inhibitor of metalloproteinases (TIMPs) and angiogenesis in relation to the depth of tumor invasion and lymph node metastasis in submucosally invasive colorectal carcinoma].[J].2005,45(6).
[15]Imaizumi T,Kouhuji K,Takeda J,etc.VEGF significance in peritoneal recurrence from gastric cancer.[J].2005,8(3).
[16]Brunelli A,Xiume F,Socci L,etc.Quality of life before and after major lung resection for lung cancer: a prospective follow-up analysis.[J].2007,84(2).
[17]Kawai N,Matsumoto Y,Okada M,etc.Matrix metalloproteinase-2 and matrix metalloproteinase-9 expressions correlate with the recurrence of intracranial meningiomas.[J].2004,66(1).
[18]Takahashi Y,Mai M.Antibody against vascular endothelial growth factor (VEGF) inhibits angiogenic switch and liver metastasis in orthotopic xenograft model with site-dependent expression of VEGF.[J].2005,24(2).
[19]Herrlinger U,Wiendl H,Renninger M,etc.Vascular endothelial growth factor (VEGF) in leptomeningeal metastasis: diagnostic and prognostic value.[J].2004,91(2).
[20]Kaminishi M.Gastric cancer with metastasis to the gingiva.[J].2004,19(7).
[21]Mitsuyama S,Ikenaga N,Suehara N,etc.Long-term quality of life after laparoscopically assisted distal gastrectomy for gastric cancer.[J].2006,16(2).
[22]Palacin A,Fondevila C,Grau JJ,etc.p53 and VEGF expression are independent predictors of tumour recurrence and survival following curative resection of gastric cancer.[J].2004,90(1).
[23]Yamao T,Ishihara S,Ohta K,etc.A Preliminary Study of Preoperative Chemotherapy Combining Irinotecan and Cisplatin in Patients with Gastric Cancer with Unresectable Para-aortic Lymph Node Metastases.[J].2004,34(5).
[24]Le AT,De Wever O,Denys H,etc.Invasion and MMP expression profile in desmoid tumours.[J].2004,90(7).
[25]Ryu JS,Mok YJ,Kim WB,etc.Impact of skip metastasis in gastric cancer.[J].2005,75(8).
[26]Takeda K,Kusunoki M,Yamakado K,etc.Prospective study of arterial infusion chemotherapy followed by radiofrequency ablation for the treatment of liver metastasis of gastric cancer.[J].2005,16(12).